In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
A new model of patient-partnered research is at the core of recently launched nonprofit organization
Research team reports on a method for altering B cells to create a new anticancer weapon
U.K.-based researchers find that mannose can impede tumors
Alligator Bioscience and Aptevo Therapeutics presented on potential therapeutic at SITC annual meeting
Sierra Oncology has shared new preclinical data supporting SRA737 as a monotherapy in ovarian cancer
Moleculin’s drug, which recently began a trial for aggressive brain tumors, counteracts resistance to checkpoint blockades
Immunicum AB is collaborating with Germany’s Merck KGaA and U.S.-based Pfizer for the evaluation of ilixadencel in combination with avelumab in a multi-indication Phase 1b/2 clinical trial
QIAGEN and NeoGenomics seek to explore potential of changes in FDA’s approach to advanced diagnostics and NGS tests

Columbia Business School report examines how cancer drugs have impacted mortality for patients
by Dr. Eyal Talor, CEL-SCI
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies

by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.